Xiasma Limited
PrivateLast Round
Grant
May 1, 2024
Est. Valuation
$260.34M
Total Funding Raised
$446.5M
Company Overview
Xiasma Limited is a software development company that builds specialist web applications, scientific software, data platforms, and operational tools for complex domains.
Sector
Healthcare & Life Sciences
Verticals
Vertical SaaS, Data Integration, Workflow Automation, Biotechnology, Compliance
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xiasma Limited Comparables
Compare Xiasma Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biogistry | 84% | |
| PhenoTips | 81% | |
| TrakGene | 79% |
For institutional investors. Book with your work email.
Xiasma Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 1, 2024 | ||||
| Grant | Mar 1, 2024 | ||||
| M&A | Aug 1, 2021 | ||||
| M&A | May 5, 2021 | ||||
| Follow-on Offering | Jul 10, 2020 | ||||
Debt | Apr 8, 2020 |
For institutional investors. Book with your work email.
Xiasma Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ROTH Capital Partners | Follow-on Offering |
| HealthCare Royalty Partners | Debt |
| Brookline Capital Markets | Follow-on Offering |
| H.C. Wainwright & Co. | Follow-on Offering |
| XT Venture Capital | Series C, Series B |
| F3 Ventures | Series D |
| MPM BioImpact | Series D, Series E, Series D Extension, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 1, 2024
$56K grant received
- Mar 1, 2024
Raised $2.1M in grant funding.
For institutional investors. Book with your work email.
Xiasma Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xiasma Limited's valuation, stock price, and market status.
Is Xiasma Limited a public or private company?
Xiasma Limited is a private company.
What is the current stock price of Xiasma Limited?
Xiasma Limited is a private company, so its shares have no public market price. Caplight tracks Xiasma Limited's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xiasma Limited worth (valuation)?
Xiasma Limited's valuation is estimated at $260.3M based on funding round data.
Can I buy Xiasma Limited stock?
Xiasma Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xiasma Limited's last funding round?
Xiasma Limited's most recent funding round was Grant on May 1, 2024.
Who are the main investors in Xiasma Limited?
Key investors in Xiasma Limited include HealthCare Royalty Partners, XT Venture Capital, MPM BioImpact, Cantor Fitzgerald, L.P..
Will Xiasma Limited IPO soon?
No public IPO plans have been announced for Xiasma Limited.
How can I track Xiasma Limited secondary market activity?
Caplight tracks bids, offers, and trades in Xiasma Limited's shares on secondary markets.